isoniazid (INH) has bacteriostatic activity against Mycobacterium tuberculosis and is one of the first line chemotherapeutic agents used in treating tuberculosis (TB)
PH severe reactions to INH such as drug fever, arthritis
acute liver disease of unknown origin
precautions
severe and sometimes fatal hepatitis associated with isoniazid therapy may occur and may develop even after many months of treatment
risk increases with age and daily alcohol consumption
carefully monitor in patients who:
are receiving phenytoin or carbamazepine concurrently
are daily users of alcohol
have severe renal dysfunction
have chronic liver disease
are > 50yrs age
ophthalmological examinations (including ophthalmoscopy) should be done before isoniazid is started and periodically thereafter, even without occurrence of visual symptoms as there is risk of optic neuritis.
category A in pregnancy - should be prescribed during pregnancy only when therapeutically necessary
lactation - monitor infants as INH passes readily into breast milk
newborn infants have limited acetylation capacity and thus at risk of toxicity
interactions
phenytoin - increased serum phenytoin levels and toxicity
carbamazepine - increased serum carbamazepine levels and toxicity